Vistagen Therapeutics Inc
For the period ended Mar 31, 2025. Filed Jun 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 17, 2025
VTGN$0.18+12.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and par value amounts)
| March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $67,131 | $119,166 |
| Marketable securities | 13,351 | — |
| Prepaid expenses and other current assets | 1,594 | 1,506 |
| Total current assets | 82,076 | 120,672 |
| Property and equipment, net | 476 | 435 |
| Right-of-use asset - operating lease | 1,335 | 1,820 |
| Other assets | 454 | 726 |
| Total assets | $84,341 | $123,653 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $653 | $1,547 |
| Accrued expenses | 8,810 | 2,235 |
| Deferred revenue - current portion | 2,588 | 791 |
| Operating lease liability - current portion | 561 | 550 |
| Total current liabilities | 12,612 | 5,123 |
| Deferred revenue - non-current portion | 391 | 2,674 |
| Operating lease liability - non-current portion | 948 | 1,570 |
| Total liabilities | 13,951 | 9,367 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2025 and March 31, 2024; no shares outstanding at March 31, 2025 and March 31, 2024 | — | — |
| Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2025 and March 31, 2024; 29,001,481 and 27,029,731 shares issued at March 31, 2025 and March 31, 2024, respectively | 29 | 27 |
| Additional paid-in capital | 481,956 | 474,441 |
| Treasury stock, at cost, 4,522 shares of common stock held at March 31, 2025 and March 31, 2024 | (3,968) | (3,968) |
| Accumulated other comprehensive gain | 5 | — |
| Accumulated deficit | (407,632) | (356,214) |
| Total stockholders’ equity | 70,390 | 114,286 |
| Total liabilities and stockholders’ equity | $84,341 | $123,653 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.